Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Novavax, with a price target of $6.00. T...

Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX)

Shares of major COVID-19 vaccine makers, Moderna ($MRNA), BioNTech ($BNTX), and Novavax ($NVAX) fell 6%, 5%, and 4%, respectively, on Monday. The d...

Market Cap	$1.21B	P/E Ratio	2.62
52W High	$11.55	52W Low	$5.01
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	62.6%	52W Position	23.9%
Overall Score	37	Value Score	40
Quality Score	47	Technical Score	25

EPS Current Est	$2.51	EPS Next Est	$-0.37
EPS Growth Est	-114.7%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVAX	$6.57	-1.79%	2.92M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVAX	$6.57	-1.8%	2.92M
3
4
5
6

NVAX

NVAX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Novavax Inc. Data in Excel

Get Novavax Inc. Data in Excel